These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27059987)

  • 41. Impact of chemoradiotherapy after disease control with chemotherapy in locally advanced pancreatic adenocarcinoma in GERCOR phase II and III studies.
    Huguet F; André T; Hammel P; Artru P; Balosso J; Selle F; Deniaud-Alexandre E; Ruszniewski P; Touboul E; Labianca R; de Gramont A; Louvet C
    J Clin Oncol; 2007 Jan; 25(3):326-31. PubMed ID: 17235048
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Hypofractionated Image-guided Radiation Therapy (3Gy/fraction) in Patients Affected by Inoperable Advanced-stage Non-small Cell Lung Cancer After Long-term Follow-up.
    Agolli L; Valeriani M; Bracci S; Nicosia L; DE Sanctis V; Enrici RM; Osti MF
    Anticancer Res; 2015 Oct; 35(10):5693-700. PubMed ID: 26408745
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Concurrent chemoradiotherapy vs radiotherapy alone in stage II nasopharyngeal carcinoma: phase III randomized trial.
    Chen QY; Wen YF; Guo L; Liu H; Huang PY; Mo HY; Li NW; Xiang YQ; Luo DH; Qiu F; Sun R; Deng MQ; Chen MY; Hua YJ; Guo X; Cao KJ; Hong MH; Qian CN; Mai HQ
    J Natl Cancer Inst; 2011 Dec; 103(23):1761-70. PubMed ID: 22056739
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Regional variation in the treatment of pancreatic adenocarcinoma: Decreasing disparities with multimodality therapy.
    Kasumova GG; Eskander MF; de Geus SWL; Neto MM; Tabatabaie O; Ng SC; Miksad RA; Mahadevan A; Rodrigue JR; Tseng JF
    Surgery; 2017 Aug; 162(2):275-284. PubMed ID: 28487044
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lymphocyte-sparing effect of stereotactic body radiation therapy compared to conventional fractionated radiation therapy in patients with locally advanced pancreatic cancer.
    Wu G; Baine MJ; Zhao N; Li S; Li X; Lin C
    BMC Cancer; 2019 Oct; 19(1):977. PubMed ID: 31640607
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dose escalation of concurrent hypofractionated radiotherapy and continuous infusion 5-FU-chemotherapy in advanced adenocarcinoma of the pancreas.
    Zimmermann FB; Jeremic B; Lersch C; Geinitz H; Hennig M; Molls M
    Hepatogastroenterology; 2005; 52(61):246-50. PubMed ID: 15783041
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictors of severe late radiotherapy-related toxicity after hyperfractionated radiotherapy with or without concomitant cisplatin in locally advanced head and neck cancer. Secondary retrospective analysis of a randomized phase III trial (SAKK 10/94).
    Ghadjar P; Simcock M; Zimmermann F; Betz M; Bodis S; Bernier J; Studer G; Aebersold DM;
    Radiother Oncol; 2012 Aug; 104(2):213-8. PubMed ID: 22726581
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dose escalation in locally advanced pancreatic cancer patients receiving chemoradiotherapy.
    Chung SY; Chang JS; Lee BM; Kim KH; Lee KJ; Seong J
    Radiother Oncol; 2017 Jun; 123(3):438-445. PubMed ID: 28464997
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Prognostic Factors for Pancreatic Cancer Patients Treated with Immune-cell Therapy.
    Makita K; Kamigaki T; Okada S; Matsuda E; Ibe H; Oguma E; Naitoh K; Takimoto R; Goto S
    Anticancer Res; 2018 Jul; 38(7):4353-4360. PubMed ID: 29970573
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Nationwide trends in chemotherapy use and survival of elderly patients with metastatic pancreatic cancer.
    van der Geest LGM; Haj Mohammad N; Besselink MGH; Lemmens VEPP; Portielje JEA; van Laarhoven HWM; Wilmink JHW;
    Cancer Med; 2017 Dec; 6(12):2840-2849. PubMed ID: 29035014
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The benefit of adjuvant radiotherapy on overall survival in resected stage I to II pancreatic cancer: A propensity-adjusted analysis.
    Lin ZB; Song JY; Li AC; Chen C; Huang XX; Xu BH
    PLoS One; 2020; 15(12):e0243170. PubMed ID: 33315874
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Reduced Risk of Severe Radiation-Induced Lymphopenia in Carbon Ion Radiation Therapy for Locally Advanced Pancreatic Cancer: A Comparative Analysis of Carbon Versus Photon Therapy.
    Yang G; Koom WS; Lee BM; Isozaki T; Shinoto M; Yamada S; Seong J
    Int J Radiat Oncol Biol Phys; 2024 Oct; 120(2):544-554. PubMed ID: 38713122
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Geographic disparities in surgical treatment recommendation patterns and survival for pancreatic adenocarcinoma.
    Salami A; Alvarez NH; Joshi ART
    HPB (Oxford); 2017 Nov; 19(11):1008-1015. PubMed ID: 28838634
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of chemoradiotherapy on the survival of unresectable locally advanced pancreatic cancer: a retrospective cohort analysis.
    Wang ZM; Ma HB; Meng Y
    BMC Gastroenterol; 2023 Apr; 23(1):107. PubMed ID: 37020202
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pancreaticoduodenectomy following chemoradiotherapy for locally advanced adenocarcinoma of the pancreatic head.
    Denost Q; Laurent C; Adam JP; Capdepont M; Vendrely V; Collet D; Cunha AS
    HPB (Oxford); 2013 Sep; 15(9):716-23. PubMed ID: 23458326
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Body mass index does not affect the survival of pancreatic cancer patients.
    Jiang QL; Wang CF; Tian YT; Huang H; Zhang SS; Zhao DB; Ma J; Yuan W; Sun YM; Che X; Zhang JW; Chu YM; Zhang YW; Chen YT
    World J Gastroenterol; 2017 Sep; 23(34):6287-6293. PubMed ID: 28974895
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The effect of primary tumor radiotherapy in patients with Unresectable stage IV Rectal or Rectosigmoid Cancer: a propensity score matching analysis for survival.
    Wang G; Wang W; Jin H; Dong H; Chen W; Li X; Li G; Li L
    Radiat Oncol; 2020 May; 15(1):126. PubMed ID: 32460810
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer.
    Saad ED; Reis PT; Borghesi G; Machado MC; Simon SD; Tabacof J; Gansl RC
    Rev Assoc Med Bras (1992); 2010; 56(1):22-6. PubMed ID: 20339781
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The influence of adjuvant radiotherapy dose on overall survival in patients with resected pancreatic adenocarcinoma.
    Hall WA; Colbert LE; Liu Y; Gillespie T; Lipscomb J; Hardy C; Kooby DA; Prabhu RS; Kauh J; Landry JC
    Cancer; 2013 Jun; 119(12):2350-7. PubMed ID: 23625519
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Survival and prognostic factors in patients with pancreatic squamous cell carcinoma.
    Tella SH; Kommalapati A; Yadav S; Bergquist JR; Truty MJ; Durgin L; Ma WW; Cleary SP; McWilliams RR; Mahipal A
    Eur J Surg Oncol; 2019 Sep; 45(9):1700-1705. PubMed ID: 31118133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.